Article in Infection and immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 3 institutions in 2 countries.
Anne TersteegenInstitute of Medical Microbiology and Hospital Hygiene, Heinrich Heine University, Düsseldorf, Germany.ORCID 0000-0001-5193-2471
Ursula R SorgInstitute of Medical Microbiology and Hospital Hygiene, Heinrich Heine University, Düsseldorf, Germany.
Richard Virgen-SlaneLaboratory of Molecular Immunology, Infectious and Inflammatory Diseases Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.
Marcel HelleInstitute of Medical Microbiology and Hospital Hygiene, Heinrich Heine University, Düsseldorf, Germany.
Patrick PetzschBiological and Medical Research Center (BMFZ), Heinrich Heine University, Düsseldorf, Germany.
Ildiko R DunayInstitute of Inflammation and Neurodegeneration, Otto-von-Guericke-University, Magdeburg, Germany.
Karl KöhrerBiological and Medical Research Center (BMFZ), Heinrich Heine University, Düsseldorf, Germany.
Daniel DegrandiInstitute of Medical Microbiology and Hospital Hygiene, Heinrich Heine University, Düsseldorf, Germany.ORCID 0000-0001-6281-0357
Carl F WareLaboratory of Molecular Immunology, Infectious and Inflammatory Diseases Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.
Klaus PfefferInstitute of Medical Microbiology and Hospital Hygiene, Heinrich Heine University, Düsseldorf, Germany klaus.pfeffer@hhu.de.ORCID 0000-0002-5652-6330
Heinrich Heine University Düsseldorf · DESanford Burnham Prebys Medical Discovery Institute · USOtto-von-Guericke-Universität Magdeburg · DE
Funding
Overriding the Immune Evasion Tactics of CoronavirusR01AI158552 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI WARE, CARL F · 2020 to 2024
$3.0M
NIAID NIH HHS R01 AI158552
6 · The paper itself
Abstract
The lymphotoxin β receptor (LTβR) plays an essential role in the initiation of immune responses to intracellular pathogens. In mice, the LTβR is crucial for surviving acute toxoplasmosis; however, until now, a functional analysis was largely incomplete. Here, we demonstrate that the LTβR is a key regulator required for the intricate balance of adaptive immune responses.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Lymphotoxin β Receptor: a Crucial Role in Innate and Adaptive Immune Responses against Toxoplasma gondii. · full record | OpenQuestion